Avience Biomedicals IPO — Listing Performance
Avience Biomedicals delivered a blockbuster debut, closing its first session 99.5% above the issue price, after the issue was subscribed an extraordinary 267.95 times.
Avience Biomedicals IPO facts & figures
| Issue category | SME |
|---|---|
| Issue open date | 18-Jun-2026 |
| Listing date | 25-Jun-2026 |
| Issue size | ₹28.53 crore |
| Overall subscription | 267.95x |
| Issue price | ₹208 |
| Listing-day close | ₹414.95 (99.5%) |
| Recent market price | ₹355.85 (71.08% vs issue) |
| Identifiers | NSE: AVIENCE · ISIN: INE0V9I01017 |
Figures are compiled from public market data and refreshed when our dataset updates. Verify against BSE/NSE records before acting on them.
How the listing went
Avience Biomedicals opened for subscription on 18-Jun-2026 as a SME issue raising about ₹29 crore. The shares were priced at ₹208 and made their debut on 25-Jun-2026, closing the first session at ₹414.95 — a listing-day change of 99.5%.
As of our last data refresh the stock trades around ₹355.85, 71.08% above the issue price.
Every IPO in our archive gets this same treatment: real issue data, the actual listing-day result, and where the price stands now — so you can judge how debut hype translated into outcomes. Compare more debuts on the IPO listing-performance archive or check live grey-market sentiment on the GMP board.
Avience Biomedicals IPO FAQs
What was the Avience Biomedicals IPO listing price?
Avience Biomedicals closed at ₹414.95 on its listing day (25-Jun-2026), against an issue price of ₹208 — a listing-day change of 99.5%.
How many times was the Avience Biomedicals IPO subscribed?
The issue was subscribed about 267.95 times overall.
Was the Avience Biomedicals IPO profitable for allottees?
On listing day, yes: allottees who sold at the closing price made about 99.5% over the issue price. Longer-term outcomes depend on when shares were sold.